Skip to main content
Top
Published in: BMC Infectious Diseases 1/2018

Open Access 01-12-2018 | Research article

Evaluation of Senegal’s prevention of mother to child transmission of HIV (PMTCT) program data for HIV surveillance

Authors: Ousmane Diouf, Astou Gueye-Gaye, Moussa Sarr, Abdou Salam Mbengue, Christopher S. Murrill, Jacob Dee, Papa Ousmane Diaw, Ndeye Fatou Ngom-Faye, Pape Amadou Niang Diallo, Carlos Suarez, Massaer Gueye, Aminata Mboup, Coumba Toure-Kane, Souleymane Mboup

Published in: BMC Infectious Diseases | Issue 1/2018

Login to get access

Abstract

Background

With the expansion of Prevention of Mother to Child Transmission (PMTCT) services in Senegal, there is growing interest in using PMTCT program data in lieu of conducting unlinked anonymous testing (UAT)-based ANC Sentinel Surveillance. For this reason, an evaluation was conducted in 2011–2012 to identify the gaps that need to be addressed while transitioning to using PMTCT program data for surveillance.

Methods

We conducted analyses to assess HIV prevalence rates and agreements between Sentinel Surveillance and PMTCT HIV test results. Also, a data quality assessment of the PMTCT program registers and data was conducted during the Sentinel Surveillance period (December 2011 to March 2012) and 3 months prior. Finally, we also assessed selection bias, which was the percentage difference from the HIV prevalence among all women enrolled in the antenatal clinic and the HIV prevalence among women who accepted PMTCT HIV testing.

Results

The median site HIV prevalence using routine PMTCT HIV testing data was 1.1% (IQR: 1.0) while the median site prevalence from the UAT HIV Sentinel Surveillance data was at 1.0% (IQR: 1.6). The Positive per cent agreement (PPA) of the PMTCT HIV test results compared to those of the Sentinel Surveillance was 85.1% (95% CI 77.2–90.7%), and the percent-negative agreement (PNA) was 99.9% (95% CI 99.8–99.9%). The overall HIV prevalence according to UAT was the same as that found for women accepting a PMTCT HIV test and those who refused, with percent bias at 0.00%. For several key PMTCT variables, including “HIV test offered” (85.2%), “HIV test acceptance” (78.0%), or “HIV test done” (58.8%), the proportion of records in registers with combined complete and valid data was below the WHO benchmark of 90%.

Conclusions

The PPA of 85.1 was below the WHO benchmarks of 96.6%, while the combined data validity and completeness rates was below the WHO benchmark of 90% for many key PMTCT variables. These results suggested that Senegal will need to reinforce the quality of onsite HIV testing and improve program data collection practices in preparation for using PMTCT data for surveillance purposes.
Literature
1.
go back to reference Agence Nationale de la Statistique and ICF International (2012). 2010-11 Senegal Demographic and Health and Multiple Indicators Survey: Key Findings. Calverton: ANSD and ICF International; 2012. Agence Nationale de la Statistique and ICF International (2012). 2010-11 Senegal Demographic and Health and Multiple Indicators Survey: Key Findings. Calverton: ANSD and ICF International; 2012.
3.
go back to reference Ngom Faye NF. Rapport sur La Prévention de la Transmission Mère-enfant du VIH au Sénégal. République du Sénégal, Ministère de la Santé et Action sociale, Division de la lutte contre le Sida et les Infections Sexuellement Transmissibles; 2014. Ngom Faye NF. Rapport sur La Prévention de la Transmission Mère-enfant du VIH au Sénégal. République du Sénégal, Ministère de la Santé et Action sociale, Division de la lutte contre le Sida et les Infections Sexuellement Transmissibles; 2014.
4.
go back to reference Division de la lutte contre le Sida et les Infections Sexuellement Transmissibles. Synthèse Prévention de la Transmission Mère-Enfant. République du Sénégal, Ministère de la Santé et Action sociale, Division de la lutte contre le Sida et les Infections Sexuellement Transmissibles; 2014 Division de la lutte contre le Sida et les Infections Sexuellement Transmissibles. Synthèse Prévention de la Transmission Mère-Enfant. République du Sénégal, Ministère de la Santé et Action sociale, Division de la lutte contre le Sida et les Infections Sexuellement Transmissibles; 2014
5.
go back to reference World Health Organization/UNAIDS 7.10. UNAIDS/WHO Working Group on Global HIV/AIDS & STI Surveillance. Guidelines for conducting HIV sentinel serosurveys among pregnant women and other groups. Geneva: WHO/UNAIDS; 2003. World Health Organization/UNAIDS 7.10. UNAIDS/WHO Working Group on Global HIV/AIDS & STI Surveillance. Guidelines for conducting HIV sentinel serosurveys among pregnant women and other groups. Geneva: WHO/UNAIDS; 2003.
6.
go back to reference Stover J, Brown T, Puckett R, Peerapatanapokin W. Updates to the Spectrum/estimations and projections package model for estimating trends and current values for key HIV indicators. AIDS. 2017;31(Suppl 1):S5–S11.CrossRef Stover J, Brown T, Puckett R, Peerapatanapokin W. Updates to the Spectrum/estimations and projections package model for estimating trends and current values for key HIV indicators. AIDS. 2017;31(Suppl 1):S5–S11.CrossRef
7.
go back to reference GBD 2015 HIV Collaborators. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV. 2016;3(8):e361–87.CrossRef GBD 2015 HIV Collaborators. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV. 2016;3(8):e361–87.CrossRef
10.
go back to reference Marsh KA, Bolu O, Bodika S, Seipone K, Wonkongkathep S, Baryarama F, Yansaneh A, Eure-Miller C, Garcia-Calleja JM. How can PMTCT program data be used for the purposes of HIV surveillance? jHASE. 2010;2:5. Marsh KA, Bolu O, Bodika S, Seipone K, Wonkongkathep S, Baryarama F, Yansaneh A, Eure-Miller C, Garcia-Calleja JM. How can PMTCT program data be used for the purposes of HIV surveillance? jHASE. 2010;2:5.
11.
go back to reference Young PW, Mahomed M, Horth RZ, Shiraishi RW, Jani IV. Routine data from prevention of mother-to-child transmission (PMTCT) HIV testing not yet ready for HIV surveillance in Mozambique: a retrospective analysis of matched test results. BMC Infect Dis. 2013;13:96.CrossRef Young PW, Mahomed M, Horth RZ, Shiraishi RW, Jani IV. Routine data from prevention of mother-to-child transmission (PMTCT) HIV testing not yet ready for HIV surveillance in Mozambique: a retrospective analysis of matched test results. BMC Infect Dis. 2013;13:96.CrossRef
12.
go back to reference Sirengo M, Rutherford GW, Otieno-Nyunya B, Kellogg TA, Kimanga D, Muraguri N, Umuro M, Mirjahangir J, Stein E, Ndisha M, Kim AA. Evaluation of Kenya's readiness to transition from sentinel surveillance to routine HIV testing for antenatal clinic-based HIV surveillance. BMC Infect Dis. 2016;16(1):113.CrossRef Sirengo M, Rutherford GW, Otieno-Nyunya B, Kellogg TA, Kimanga D, Muraguri N, Umuro M, Mirjahangir J, Stein E, Ndisha M, Kim AA. Evaluation of Kenya's readiness to transition from sentinel surveillance to routine HIV testing for antenatal clinic-based HIV surveillance. BMC Infect Dis. 2016;16(1):113.CrossRef
13.
go back to reference Gonese E, Mushavi A, Mungati M, Mhangara M, Dzangare J, Mugurungi O, Dee J, Kilmarx PH, Shambira G, Tshimanga MT, Hargrove JI. Zimbabwe ready to transition from anonymous unlinked sero-surveillance to using prevention of mother to child transmission of HIV (PMTCT) program data for HIV surveillance?: results of PMTCT utility study. 2012 BMC Infect Dis. 2016;16(1):97.CrossRef Gonese E, Mushavi A, Mungati M, Mhangara M, Dzangare J, Mugurungi O, Dee J, Kilmarx PH, Shambira G, Tshimanga MT, Hargrove JI. Zimbabwe ready to transition from anonymous unlinked sero-surveillance to using prevention of mother to child transmission of HIV (PMTCT) program data for HIV surveillance?: results of PMTCT utility study. 2012 BMC Infect Dis. 2016;16(1):97.CrossRef
14.
go back to reference Seguy N, Hladik W, Munyisia E, Bolu O, Marum LH, Diaz T. Can data from programs for the prevention of mother-to-child transmission of HIV be used for HIV surveillance in Kenya? Public Health Rep. 2006;121(6):695–702.CrossRef Seguy N, Hladik W, Munyisia E, Bolu O, Marum LH, Diaz T. Can data from programs for the prevention of mother-to-child transmission of HIV be used for HIV surveillance in Kenya? Public Health Rep. 2006;121(6):695–702.CrossRef
15.
go back to reference Fabiani M, Yoti Z, Nattabi B, Ayella EO, Opio AA, Musinguzi J, García Calleja JM, Declich S. Adjusting HIV prevalence data from a program for the prevention of mother-to-child transmission for surveillance purposes in Uganda. J Acquir Immune Defic Syndr. 2007;46(3):328–31.CrossRef Fabiani M, Yoti Z, Nattabi B, Ayella EO, Opio AA, Musinguzi J, García Calleja JM, Declich S. Adjusting HIV prevalence data from a program for the prevention of mother-to-child transmission for surveillance purposes in Uganda. J Acquir Immune Defic Syndr. 2007;46(3):328–31.CrossRef
16.
go back to reference Seipone K. Utility of PMTCT program data for HIV surveillance in Botswana - Preliminary results. In: 2nd Global HIV/AIDS Surveillance Meeting (Session VIIB). Bangkok; 2009. Seipone K. Utility of PMTCT program data for HIV surveillance in Botswana - Preliminary results. In: 2nd Global HIV/AIDS Surveillance Meeting (Session VIIB). Bangkok; 2009.
17.
go back to reference Hladik W, Masupu K, Roels T, Plipat T, Kaharuza F, Bunnell R, Seguy N, Marum LH. Prevention of mother-to-child transmission and voluntary counseling and testing programme data: what is their utility for HIV surveillance? AIDS. 2005;19(Suppl 2):S19–24.CrossRef Hladik W, Masupu K, Roels T, Plipat T, Kaharuza F, Bunnell R, Seguy N, Marum LH. Prevention of mother-to-child transmission and voluntary counseling and testing programme data: what is their utility for HIV surveillance? AIDS. 2005;19(Suppl 2):S19–24.CrossRef
18.
go back to reference Parekh BS, Kalou MB, Alemnji G, Ou CY, Gershy-Damet GM, Nkengasong JN. Scaling up HIV rapid testing in developing countries: comprehensive approach for implementing quality assurance. Am J Clin Pathol. 2010;134(4):573–84.CrossRef Parekh BS, Kalou MB, Alemnji G, Ou CY, Gershy-Damet GM, Nkengasong JN. Scaling up HIV rapid testing in developing countries: comprehensive approach for implementing quality assurance. Am J Clin Pathol. 2010;134(4):573–84.CrossRef
19.
go back to reference Ayana G. Ensuring Accuracy and Reliability of HIV Testing in Ethiopia. African Society of Laboratory Medicine Consultative Meeting: Improving Access and Increasing Quality of HIV Testing in Africa. Dar es Salaam: United Republic of Tanzania; 2014. Ayana G. Ensuring Accuracy and Reliability of HIV Testing in Ethiopia. African Society of Laboratory Medicine Consultative Meeting: Improving Access and Increasing Quality of HIV Testing in Africa. Dar es Salaam: United Republic of Tanzania; 2014.
21.
go back to reference Dee J, Garcia Calleja JM, Marsh K, Zaidi I, Murrill C, Swaminathan M. HIV Surveillance Among Pregnant Women Attending Antenatal Clinics: Evolution and Current Direction. JMIR Public Health Surveill. 2017;3(4):e85.CrossRef Dee J, Garcia Calleja JM, Marsh K, Zaidi I, Murrill C, Swaminathan M. HIV Surveillance Among Pregnant Women Attending Antenatal Clinics: Evolution and Current Direction. JMIR Public Health Surveill. 2017;3(4):e85.CrossRef
22.
go back to reference Mbengue MAS, Sarr M, Diaw PA, Diallo PAN, Toure MD, Ngom-Faye NF, Gueye B, Toure-Kane NCT, Mboup S. Establishing a national laboratory quality system for HIV diagnosis and monitoring in resource-limited settings: experience from Senegal. Afr J Lab Med. 2016;5(2):51–4.CrossRef Mbengue MAS, Sarr M, Diaw PA, Diallo PAN, Toure MD, Ngom-Faye NF, Gueye B, Toure-Kane NCT, Mboup S. Establishing a national laboratory quality system for HIV diagnosis and monitoring in resource-limited settings: experience from Senegal. Afr J Lab Med. 2016;5(2):51–4.CrossRef
Metadata
Title
Evaluation of Senegal’s prevention of mother to child transmission of HIV (PMTCT) program data for HIV surveillance
Authors
Ousmane Diouf
Astou Gueye-Gaye
Moussa Sarr
Abdou Salam Mbengue
Christopher S. Murrill
Jacob Dee
Papa Ousmane Diaw
Ndeye Fatou Ngom-Faye
Pape Amadou Niang Diallo
Carlos Suarez
Massaer Gueye
Aminata Mboup
Coumba Toure-Kane
Souleymane Mboup
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2018
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-018-3504-z

Other articles of this Issue 1/2018

BMC Infectious Diseases 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.